HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Genzyme Corporation in connection with its RENAGEL® (sevelamer hydrochloride) tablets, 400 mg and 800 mg.
